Hardships are greatest in younger cancer survivors vs patients without cancer history.
Most patients in the study received crizotinib; prognosis worse when more organs had tumors at diagnosis.
Patients with malignant pleural effusion may care more about relieving symptoms such as dyspnea as opposed to achieving pleurodesis.
Higher suicide rates observed for cancers with poor prognosis, including pancreatic and lung cancer.
In seniors, risk for arterial thromboembolic events peaked in the 30 days immediately before cancer diagnosis.
A 13-fold increased risk was found in native lung for those receiving single lung transplant.
Mortality rate was lower for habitually active patients and for those who started exercising after their cancer diagnosis.
The approval was based on data from the IMpower 150 trial, an open-label study involving 1202 patients with stage IV metastatic NSq NSCLC who had not received prior chemotherapy for metastatic disease, but could have received prior EGFR or ALK kinase inhibitor if appropriate, regardless of PD-L1 or T-effector gene status and ECOG performance status 0 or 1.
The concept of thirdhand smoke was originally introduced in 1953, when rodent studies first demonstrated the carcinogenic effects of the residue from tobacco smoke.
The implementation guide is designed to increase levels of lung cancer screening in heavy smokers.
The smartphone-based app can cut both the severity of advanced cancer patients' reported pain and hospital admissions.
There is an urgent need for coordinated, comprehensive, personalized care for cancer survivors and caregivers.
The median duration of reported cough at study entry was 52 weeks and it was severe enough in more than half of participants that it warranted treatment.
Being 64 years or younger, being male, having underwent a thoracotomy, and using adjuvant therapy were all associated with a greater risk for persistent opioid use.
More frequent postsurgical surveillance is not associated with improved survival in non-small cell lung cancer.
Annual number of deaths from lung cancer are expected to continue to decrease despite the growth and aging of the US population.
The FDA has approved Lorbrena (lorlatinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic NSCLC.
The FDA has approved Keytruda in combination with carboplatin and either paclitaxel or nab-paclitaxel for the first-line treatment of patients with metastatic squamous NSCLC.
Both overall and progression-free survival were longer with durvalumab vs placebo.
To investigate the association between this commonly used antihypertensive class and lung cancer, researchers conducted a population based cohort study involving 992,061 patients from the United Kingdom Clinical Practice Research Datalink.
Patients who had video-assisted thoracoscopic surgery were less likely to use opioids long term.
Tobacco control could prevent more cancer deaths than any other strategy.
Significant improvements were seen with the addition of atezolizumab to CnP in stage IV non-squamous non-small cell lung cancer, regardless of patient PD-L1 status.
Most patients with metastatic non-small cell lung cancer who received targeted therapy based on plasma result achieved clinical response.
In individuals aged 18 to 35, California has had larger drops in smoking initiation, intensity, and higher rates of quitting.
Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLCOctober 19, 2018
Researchers investigated whether the rates of immune-related adverse events linked to treatment with nivolumab or pembrolizumab were similar across 2 different cancer types.
Longer progression-free survival was significantly longer in patients with ALK-positive disease who did not previously take an ALK inhibitor.
Classifier integrates relative abundance of 2 plasma proteins with clinical risk prediction model for lung nodules.
The approval was based on data from the ARCHER 1050 open-label, active controlled study which randomized patients with unresectable, metastatic NSCLC to treatment with either dacomitinib (N=227) or gefitinib (N=225).
Salvage treatment for recurrence of early-stage non-small cell lung cancer after initial treatment with stereotactic ablative radiotherapy improved patient survival.